V. Michael Holers

The American College of Rheumatology Research and Education Foundation was established in 1985 with a mission of advancing research and training to improve the health of people with rheumatic diseases. Since its founding, the REF has promoted and advanced the field of rheumatology by funding research, training and education opportunities for clinicians, students, health professionals, researchers and academic institutions.

Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA.

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts.

The American College of Rheumatology is an organization for physicians and health professionals. The non-profit company is based in Atlanta, GA. The company was founded by Göran Albert Torstensson Ando.